Low Molecular Weight Fucoidan from Saccharina Japonica Ameliorates the Antioxidant Capacity and Reduces Plaque Areas in Aorta in Apoe-Deficient Mice with Atherosclerosis

A comprehensive review of preparation and pharmacology of low molecular weight fucoidan

Fucoidan is a type of sulfated fucans originated from many marine animals and algae, its unique molecular characteristics rich in L-fucose and sulfate ester group give it a wide range of biological properties. The natural polysaccharide has been used as a clinical drug for kidney disease for many years. However, high molecular weight associated defects, low water solubility and high viscosity, reduce its bioavailability. Consequently, low molecular weight fucoidan (LMWF) with better physicochemical properties originally has been widely studied its biological properties and once regarded as a substitute of heparin for its anticoagulant activity. Presently, large number of researches reported its various bioactivities, including anti-coagulation, anti-oxidation, anti-inflammation, anti-tumor, etc., but the LMWFs prepared by different methods from various species possess distinct molecular characteristics, which results in discrepant biological activities and the underlying mechanisms. Based on the research progress of LMWF, this review article comprehensively overviewed the preparation methods, toxicity, and pharmacology, which highlights LMWF as a valuable marine active substance for developing marine functional foods and drugs.

Fucoidan-induced reduction of lipid accumulation in foam cells through overexpression of lysosome genes

Atherosclerosis (AS) is the common basis for the onset of cardiovascular events. The lipid metabolism theory considers foam cell formation as an important marker for the initiation of AS. Fucoidan is an acidic polysaccharide that can reduce lipid accumulation in foam cells. Studies show that tea polysaccharides can be transported to lysosomes via the tubulin pathway. However, the specific mechanism of action of fucoidan on foam cells has not been extensively studied. Therefore, we further explored the mechanism of action of fucoidan and evaluated whether it could reduce lipid accumulation in foam cells by affecting the expression of lysosomal pathway-related genes and proteins. In this study, three inhibitors, CPZ, EIPA, and colchicine, were used to inhibit endocytosis, macropinocytosis, and the tubulin pathway, respectively, to study the pathways of action. Transcriptomics and proteomics analysis, as well as western blotting and qRT-PCR were used to determine the effects of fucoidan and the inhibitors on lysosomal genes and proteins. Fucoidan could enter foam cells through both endocytosis and via macropinocytosis, and then further undergo intracellular transport via the tubulin pathway. After fucoidan treatment, the expression of lysosomal pathway-related genes and proteins including LAMP2, AP3, AP4, MCOLN1, and TFEB in foam cells increased significantly (P < 0.01). However, the expression of lysosomal genes and proteins after colchicine intervention was comparable with that in the model group. Therefore, the tubulin pathway inhibited by colchicine is an important pathway for the transport and distribution of fucoidan within cells. In summary, fucoidan may be transported to lysosomes via the tubulin pathway and may enhance the expression of lysosomal genes, promoting autophagy, thereby accelerating lipid clearance in foam cells. Due to its significant lipid-lowering effect, it can be used in the clinical treatment of AS.